Speciality Medicines is currently locked at its upper circuit limit of Rs. 298.80, up by 14.20 points or 4.99% from its previous closing of Rs. 284.60 on the BSE.
The scrip opened at Rs. 284.00 and has touched a high and low of Rs. 298.80 and Rs. 270.80 respectively. So far 79000 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 298.80 on 22-Apr-2026 and a 52 week low of Rs. 121.10 on 06-Apr-2026.
Last one week high and low of the scrip stood at Rs. 298.80 and Rs. 181.00 respectively. The current market cap of the company is Rs. 262.52 crore.
The promoters holding in the company stood at 43.43%, while Institutions and Non-Institutions held 0.24% and 56.33% respectively.
Speciality Medicines has finalized a commercial arrangement with an international entity specializes in importing and distributing the Pharmaceutical Finished Products, supporting its future growth. Under the said deal, the said entity has agreed to distribute, market and sell the Products of the company of value of $1.5 million (an approximate value of Rs 14 crore), subject to terms and conditions as mutually agreed.
The arrangement is expected to significantly enhance the Company’s distribution network and revenue visibility.
Speciality Medicines is primarily engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.
| Company Name | CMP |
|---|---|
| Redington | 218.75 |
| Adani Enterprises | 2500.05 |
| Amrapali Industries | 17.50 |
| Rashi Peripheral | 544.25 |
| PDS | 291.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: